MARY RENFROW: Open Payments
NPI 1801372800 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$338 in 16 payments from 8 companies in 2025. Trend: 2023 $313 · 2024 $394 · 2025 $338
Food & beverage: $338
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $80 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $68 |
| Ardelyx, Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| GENZYME CORPORATION | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Janssen Biotech, Inc. | 1 | $17 |
Products named: XIFAXAN, SKYRIZI, IBSRELA, DUPIXENT, GATTEX, EOHILIA, ZENPEP, OMVOH.
Industry payments across MD — which companies pay providers there.
